March 16, 2026 — Cytokinetics has announced four presentations related to Myqorzo (aficamten) at the American College of Cardiology (ACC) Annual Scientific Session & Expo, March 28–30, 2026, New Orleans, LA. Recently approved for the treating adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) by the U.S. Food and Drug Administration, European Commission and the China National Medical Products Administration, Myqorzos an allosteric and reversible inhibitor of cardiac myosin motor activity. In patients with oHCM, myosin inhibition with Myqorzo reduces cardiac contractility and consequently, left ventricular outflow tract (LVOT) obstruction.
“We are pleased to contribute further evidence that we believe will help physicians and patients with clinical decision making,” said Stephen Heitner, M.D., Senior Vice President, Clinical Research and Development. “The new data can help empower evidence-based choices of therapy for patients living with symptomatic oHCM, showing that aficamten improves exercise capacity, when compared to placebo or the beta blocker, metoprolol, while maintaining its safety profile.”
Scientific Presentations Include:
- Evaluation of Aficamten or Beta-Blocker Monotherapy Versus Placebo in Patients with Obstructive Hypertrophic Cardiomyopathy: A Pooled Analysis of SEQUOIA-HCM and MAPLE-HCM (1186-09), Moderated Poster Presentation, P. Christian Schulze, M.D., Ph.D., Chair of the Department of Medicine and Division of Cardiology, Angiology and Intensive Medical Care at the University Hospital Jena
- Clinical Implications Associated with Temporary Treatment Interruption and Reinitiation of Aficamten Therapy in Obstructive Hypertrophic Cardiomyopathy (906-11), Oral Presentation, Martin Maron, M.D., Director, Hypertrophic Cardiomyopathy Center, Lahey Hospital & Medical Center; and National Principal Investigator of SEQUOIA-HCM
- Aficamten Versus Metoprolol in Patients with Hypertension and Obstructive Hypertrophic Cardiomyopathy (1395-221), Poster Presentation, Ahmad Masri, M.D., MS, Director of the Hypertrophic Cardiomyopathy Center at Oregon Health & Science University
- Electrocardiographic Changes and Associations with Echocardiographic Changes in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: Insights from the SEQUOIA-HCM Trial (1514-243), Poster Presentation, Alberto Foà, M.D., Ph.D., Cardiologist, Brigham and Women's Hospital, Harvard Medical School; Heart Failure and Transplant Unit - IRCCS Azienda Ospedaliero-Universitaria di Bologna
For additional information, visit www.cytokinetics.com
April 02, 2026 
